This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Last week, four of the world’s largest automakers (Ford (NYSE:F), GM (NYSE:GM), BMW and Renault) launched a blockchain1 alliance that could represent a tectonic shift, not just in the adoption of blockchain tech, but also in the race to lead the next iteration of the “automobile” industry.
STT F DTK ICE NYTAB GM
NEW YORK (Reuters) - Stock exchange operator IEX Group has withdrawn a stalled proposal with U.S. regulators for a new corporate listings program in partnership with a Silicon Valley-based startup aimed at promoting long-term growth ahead of short-term profits.
IEX NDAQ WYNN DTK ICE
Silicon Valley is still finding plenty of reasons, and money, to pour into the cryptocurrency industry.
Tsvetana is a writer for the U.S.-based Divergente LLC consulting firm with over a decade of experience writing for news outlets such as iNVEZZ and…
NEW YORK (Reuters) - Nasdaq Inc (NDAQ.O) and a Wall Street watchdog will raise fees for private stock trading platforms, such as “dark pools,” that report trade executions to a Nasdaq-run entity, in response to higher operational costs and off-exchange trading volumes, according to a recent regulatory filing.
NDAQ DTK ICE
2018-08-15 investorplace - 1
Rising interest rates generally prove a boon for financial stocks, but if turmoil in Turkey turns into an outright contagion that infects the rest of the world, it’s unlikely any sector would be spared regardless of the backdrop. Never mind the fact that the wrong headline can pull the rug out from underneath the market without any warning.
DFS SQ C RF DTK PYPL KEY GS VIRT AMTD ICE ENVA EBAY
Bitcoin's narrative is hard to pin down, but as with early internet stocks, real traction will come in time, cryptocurrency advocate Meltem Demirors told CNBC on Monday.
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
2018-08-12 seekingalpha - 4
Dan Loeb's 13F portfolio value increased from $13.32B to $14.35B this quarter. The number of positions decreased from 40 to 38.
ATHTF STZ.B TWX CRM DOW DOV MELI PBF TPRE WP KDMN STZ UTX BKI TWC PVH DVMT FPAC.U GOOGL MSFT APY MHK TPNTF GRBK FB DOV.WI LEN NXPI PYPL NFLX BAX GOOG LEN.B MPC PAGS ADBE SPGI EGN MON ICE SHY CWH EA WYNN ANTM DWDP BID BLK V DHR ANTX
Many factors make up the market structure of a commodity. When I analyze a specific raw material market for clues about the path of least resistance for prices, the market structure is one of my favorite fundamental tools.
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET